 BOSTON and LOUISVILLE, Ky. , May 11, 2021 GLOBE NEWSWIRE -- Talaris Therapeutics, Inc. Nasdaq: TALS, a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of 17.00 per share. The gross proceeds of the offering were approximately 150.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on May 7, 2021 under the symbol TALS. All shares in the offering were offered by Talaris Therapeutics. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions. 